Charles Mullighan,MD[slides]-Genomic Classification-Corrected
In his presentation, Charles Mullighan, MD, discusses the genomic classification and diagnostic strategies for Acute Lymphoblastic Leukemia (ALL). He covers three main areas: B-cell ALL (BOL), its implications for risk stratification and diagnosis, and insights into the classification of T-cell ALL.
![Charles Mullighan,MD[slides]-Genomic Classification-Corrected](https://oncologytubecom.cdn.ypt.me/videos/video_230825050715_v58a3/video_230825050715_v58a3_thumbsV2_jpg.webp?cache=1692960590_1692960590 "Charles Mullighan,MD[slides]-Genomic Classification-Corrected")
Category:
Description:
Charles G. Mullighan, MBBS (Hons), MSc, MD-Member, St. Jude Faculty-Deputy Director, Comprehensive Cancer Center-St. Jude Children's Research Hospital
Charles Mullighan, MD, delves into the genomic classification of Acute Lymphoblastic Leukemia (ALL) and its diagnostic approaches. He covers three main areas: B-cell ALL (BOL), implications for risk stratification and diagnosis, and insights into the classification of T-cell ALL (TOL).
REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS
AML-ALL US - Online content available - https://aml-allus2023.md-education.com/register/
AML-ALL EU - Registration open - https://aml-alleu2023.md-education.com/register/
MPN-MDS EU - registration open - https://mpn-mdseu2023.md-education.com/register/
After a decade of genomic research, Dr. Mullighan discusses the significant progress made in the genomic classification of BOL. Studies with thousands of patients, including RNA sequencing, have identified around twenty-three subtypes of BOL, each associated with unique clinical features, minimal residual disease (MRD), and outcomes. This has led to the exploration of integrating these subtypes into clinical practice.